Thiazide diuretics are back in CKD: the case of chlorthalidone

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Sodium and volume overload are primary drivers of hypertension in chronic kidney disease (CKD).
• CKD patients typically exhibit salt-sensitive hypertension, necessitating dietary and pharmacological interventions.
• Loop diuretics are traditionally favored over thiazides in advanced CKD (Stage 4), with thiazides often considered less effective.

Purpose of the Study:

• To systematically review randomized trials evaluating the efficacy of thiazide diuretics in CKD patients.
• To assess the potential utility of thiazides in managing hypertension in advanced stages of CKD.
• To provide evidence-based insights into the role of thiazides in CKD hypertension management.

Main Methods:

• Systematic appraisal of published randomized controlled trials (RCTs) involving thiazide diuretics in CKD patients.
• Analysis of data concerning blood pressure control, sodium balance, and fluid volume reduction.
• Review of evidence from trials like the CLICK trial on specific thiazide-like diuretics (e.g., chlorthalidone).

Main Results:

• Thiazide diuretics induce a negative sodium balance, reducing body fluid volume by 1-2 liters within 2-4 weeks.
• This fluid reduction is associated with improved hypertension control in CKD patients.
• The CLICK trial demonstrated the antihypertensive efficacy of chlorthalidone in Stage 4 CKD patients with resistant hypertension.

Conclusions:

• Thiazide diuretics may be beneficial for blood pressure management even in advanced CKD stages.
• Chlorthalidone presents a potential therapeutic option for treatment-resistant hypertension in CKD, especially when alternatives are contraindicated.
• Physicians must remain vigilant for potential side effects such as hyponatremia, hypokalemia, volume depletion, and acute kidney injury. Further high-quality trials are needed to confirm efficacy for hard outcomes.